



<b>Welcome and Introduction</b>	<b>Speakers/Facilitators</b>
09:15 Signing onto platform	Dr Naila Arebi Dr Charlotte Wong
<b>Session 1 – Crohn’s disease – lectures (one hour)</b>	
09:30 Intestinal Crohn’s disease – how to choose the right drug	Dr Naila Arebi
10:00 Diet in CD – what do patients need to know?	Gabriella Porfou
<b>Session 2 – Generic skills applied to IBD part 1 (one hour)</b>	
10:30 Quality improvement in IBD – how to start and complete a project A real world scenario has been given below:  <i>“The IBD advice line had a surge in phone calls from patients during the COVID-19 pandemic. Queries range from Shielding Advice to Medication Queries to Flare Management. The IBD nursing team are overwhelmed, the average response time is 5 days and there are numerous patient complaints. You have been tasked by your lead to devise a system to manage the volume of work.”</i>	Dr Nik Kamperidis
11:00 Breakout groups <ul style="list-style-type: none"> <li>• Separate into 3 groups for interactive session</li> <li>• You have been sent an invitation from a facilitator for each group</li> </ul> <b>Group 1:</b> Action effect Diagram <b>Group 2:</b> Plan do study act (PDSAs) <b>Group 3:</b> Process map	Dr Naila Arebi Susan Barber Tracey Tyrrell
11:30 Summary Session <ul style="list-style-type: none"> <li>• All participants to re-join the General Room</li> </ul>	Dr Nik Kamperidis
<b>11.45 – 12:15 LUNCH</b>	
<b>Session 3 – Generic skills applied to IBD part 2</b>	
12:15 Critical appraisal of recent published paper using evidence to guide clinical practice. <b>Participants are advised to read the following paper before attending</b>  <i>VARSIY Study Group. Vedolizumab versus Adalimumab for moderate-to-severe Ulcerative Colitis.</i>	Dr Naila Arebi Dr Lovesh Dyall

<p><i>Lirio RA, Bornstein JD, Schreiber S. N Engl J Med. 2019 Sep 26;381(13):1215-1226.doi: 10.1056/MEJMo1905725. PMID:31553834</i></p> <ul style="list-style-type: none"> <li>• Overview of the paper (10 mins)</li> <li>• You will split into groups, as before, for the critical appraisal (40mins)</li> </ul> <p><b>Group 1</b> <b>Group 2</b> <b>Group 3</b></p> <ul style="list-style-type: none"> <li>• Each group nominates a member to present the paper having now critiqued it with facilitator in the group (10mins)</li> </ul> <p>Questions to address:</p> <ol style="list-style-type: none"> <li>1. Abstract and introduction -research questions and hypothesis</li> <li>2. Methods - study design and population/sampling bias - confounders allocation to groups</li> <li>3. Description of data and its analysis</li> <li>4. Interpretation of results</li> <li>5. Applicability and discussion</li> </ol>	Dr Arebi
<p><b>Session 4 – Ulcerative colitis</b></p> <p>13:15 Ulcerative Colitis – what’s new?</p> <p>13:45 IBD Surveillance – how to get it right</p>	<p>Dr Ravi Misra</p> <p>Professor Siwan Thomas-Gibson</p>
<b>14:15 – 14:30 BREAK</b>	
<p><b>Session 5 – Case based discussion (one hour)</b></p> <p>14:30 Active perianal disease and fistulae - a surgeon’s perspective</p> <p>15:00 Pouches and pouchitis Surgical techniques, acute &amp; chronic pouchitis, surveillance</p>	<p>Professor Omar Faiz</p> <p>Professor Sue Clark</p>
<b>15:30 PLEASE FILL IN ATTACHED FEEDBACK FORM</b>	<b>END</b>